trametinib,pembrolizumab,dabrafenib
merck,novartis
[]
 presents neotrio trial. neoadj pd1 vs induction braf/mek and then pd1 vs combo braf/mek/pd1. 50% pcr for combo therapy. no diff in efs, rfs or os. combo more toxic 55% gr 3/4 and 40% tx discontinuation #asco22 
Associate professor in Surgery at Sahlgrenska University Hospital. @sahlgrenska @SahlgrenskaAcad @goteborgUni #wcmtm #melanoma #breastcancer #surgery